Trial 3L-13-3


A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) vs Placebo in Subjects with Hepatocellular Carcinoma Who Have Received Prior Sorafenib

Type: Treatment
Phase: Phase III
Status: Not Open (Closed)
Treatments: Chemotherapy: Systemic
Randomized: Yes
USC Satellite Location: USC Newport Beach Oncology
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Anthony El-Khoueiry, M.D.
Other Trial Staff:  Ramona Lujan, R.N., Yan Ning, D.M., Charlean Ketchens, Coordinator, Marile Garcia, Coordinator, Kristy Sartor Massopust, Coordinator, Yanli Wang, D.M., Rabia Rehman, Coordinator

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.